Graham Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Graham Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,931	Closed	-$321K	–	1246
2025 Q3	$321K	Sell	5,931 -71,977	-92%	-$4.12M	0.01%	829
2025 Q2	$4.28M	Buy	77,908 +58,891	+310%	+$3.47M	0.06%	172
2025 Q1	$1.34M	Buy	+19,017	New	+$1.28M	0.02%	463
2024 Q4	–	Sell	-13,038	Closed	-$916K	–	1240
2024 Q3	$916K	Buy	13,038 +5,709	+78%	+$477K	0.02%	488
2024 Q2	$603K	Sell	7,329 -14,453	-66%	-$1.2M	0.01%	528
2024 Q1	$1.9M	Buy	+21,782	New	+$1.95M	0.04%	263
2023 Q3	–	Sell	-40,223	Closed	-$3.49M	–	1026
2023 Q2	$3.49M	Buy	+40,223	New	+$3.79M	0.1%	136
2022 Q4	–	Sell	-31,003	Closed	-$2.63M	–	1062
2022 Q3	$2.63M	Buy	31,003 +26,503	+589%	+$2.36M	0.1%	152
2022 Q2	$372K	Sell	4,500 -12,977	-74%	-$1.03M	0.02%	760
2022 Q1	$1.35M	Buy	17,477 +14,056	+411%	+$1.18M	0.05%	209
2021 Q4	$302K	Buy	+3,421	New	+$282K	0.01%	322

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Graham Capital Management's BMRN Position: Q4 2025 in Review

Graham Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,931 shares — an estimated $321K sold.

Graham Capital Management first reported a position in BMRN in Q4 2021 and held it in 11 quarters. The position peaked at $4.28M in Q2 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Graham Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Graham Capital Management sold 5,931 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $321K.
Graham Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 11 quarters.
Graham Capital Management's BioMarin Pharmaceuticals position peaked at $4.28M in Q2 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.